2-甲氧基甲基-苯甲酸酰胺 | 408538-58-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲氧基甲基-苯甲酸酰胺
• 英文名称: 2-methoxymethyl-benzoic acid amide
• 英文别名: 2-Methoxymethyl-benzoesaeure-amid；2-(Methoxymethyl)benzamide
• CAS: 408538-58-9
• 化学式: C₉H₁₁NO₂
• 分子量: 165.192
• InChiKey: UVDFFAYGMABKPN-UHFFFAOYSA-N

物化性质

• 熔点：
  101-102 °C
• 沸点：
  283.9±23.0 °C(Predicted)
• 密度：
  1.121±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-甲氧基甲基-苯甲酸酰胺 在 sodium hypobromide 作用下， 生成 2-丁基苯胺
  参考文献：
  名称：

  镁和格氏试剂对某些苄基醚的作用。第二部分 格利雅的作用试剂上ø - ，米- ，和p甲氧基-苯氧基和- methylanilines

  摘要：

  DOI：

  10.1039/jr9540004127
• 作为产物：
  描述：

  2-(methoxymethyl)benzonitrile 在 sodium hydroxide 、 双氧水 作用下， 生成 2-甲氧基甲基-苯甲酸酰胺
  参考文献：
  名称：

  镁和格氏试剂对某些苄基醚的作用。第二部分 格利雅的作用试剂上ø - ，米- ，和p甲氧基-苯氧基和- methylanilines

  摘要：

  DOI：

  10.1039/jr9540004127

文献信息

• [EN] RORγ ANTAGONIST AND APPLICATION THEREOF IN MEDICINE<br/>[FR] ANTAGONISTE DE RORγ ET SON UTILISATION EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2020011147A1

  公开（公告）日：2020-01-16

  Provided herein are compounds as RORγ antagonist having Formula (I). The compounds or pharmaceutical composition thereof can be used for regulating Retinoid-related orphan receptor gamma t (RORγt). Also provided herein are methods of preparation of the compounds and composition thereof, and uses thereof in treating or preventing RORγt mediated inflammation or autoimmune diseases in mammals, particularly humans.

  本文提供的化合物为具有式（I）的RORγ拮抗剂。这些化合物或其药物组成物可用于调节视黄醇相关孤儿受体γ（RORγt）。本文还提供了这些化合物及其组成物的制备方法，以及在治疗或预防哺乳动物，特别是人类中的RORγt介导的炎症或自身免疫疾病中的用途。
• [EN] ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ÉTHYLÈNE DIAMINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'HYPOCRÉTINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016100161A1

  公开（公告）日：2016-06-23

  The present invention is directed to ethyldiamne compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及对促进素受体的拮抗剂乙二胺化合物。本发明还涉及所述化合物在潜在的治疗或预防涉及促进素受体的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在的预防或治疗涉及促进素受体的疾病中的用途。
• Hydroxymethylbenzothiazoles Amides
  申请人：Besidski Yevgeni

  公开号：US20080070946A1

  公开（公告）日：2008-03-20

  The present invention relates to new compounds, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

  本发明涉及新化合物，或其盐，溶剂合物或溶剂化盐，其制备过程及用于制备中的新中间体，含有该化合物的药物组合物以及该化合物在治疗中的应用。
• 1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE
  申请人：Sekiguchi Yoshinori

  公开号：US20100081825A1

  公开（公告）日：2010-04-01

  Disclosed is a pharmaceutical composition comprising a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, which has an antagonistic activity on a melanin-concentrating hormone receptor. The pharmaceutical composition is useful, due to its antagonistic activity on a MCH receptor, for the prevention or treatment of a disease such as depression, anxiety disorders (e.g., generalized anxiety disorder, post traumatic stress disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder), attention deficit disorder, mania, manic-depressive disorder, schizophrenia, mood disorders, stress, sleep disorder, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, a cardiovascular diseases, hypertension, dyslipidemia, cardiac infarction, movement disorder (e.g., Parkinson's disease, epilepsy, convulsion, tremor), drug abuse and drug addiction.

  本发明揭示了一种药物组合物，其包括一种由式(I)表示的化合物或其药学上可接受的盐作为活性成分，该化合物具有对黑色素浓集激素受体的拮抗活性。该药物组合物由于其对MCH受体的拮抗活性，可用于预防或治疗抑郁症、焦虑障碍（例如广泛性焦虑症、创伤后应激障碍、恐慌症、强迫症、社交焦虑症）、注意力缺陷障碍、躁狂、躁郁症、精神分裂症、情绪障碍、压力、睡眠障碍、发作、记忆障碍、认知障碍、痴呆、健忘症、谵妄、肥胖症、进食障碍、食欲障碍、过度进食、暴食症、食物恐惧症、糖尿病、心血管疾病、高血压、脂质代谢异常、心肌梗塞、运动障碍（例如帕金森病、癫痫、抽搐、震颤）、药物滥用和药物成瘾等疾病的预防或治疗。
• HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON 11- -HYDROXYSTEROID DEHYDROGENASE TYPE I
  申请人：Shionogi & Co., Ltd.

  公开号：EP1953145A1

  公开（公告）日：2008-08-06

  Disclosed is a compound useful as a type I 11βhydroxysteroid dehydrogenase inhibitor. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R1 is optionally substituted alkyl or the like, one of R2 and R4 is a group of formula: -Y-R5, wherein Y is -O- or the like, R5 is substituted alkyl (the substituent is optionally substituted cycloalkyl or the like), optionally substituted branched alkyl or the like, the other of R2and R4 is hydrogen or optionally substituted alkyl, R3 is a group of formula: -C(=O)-Z-R6, wherein Z is -NR7- or -NR7-W-, R6 is optionally substituted cycloalkyl or the like, R7 is hydrogen or optionally substituted alkyl, W is optionally substituted alkylene, X is =N- or the like, with the proviso that compounds wherein R2 is 2-(morphorino)ethoxy, R3 is N-(1-adamantyl)carbamoyl and R1 is benzyl are excluded.

  本发明公开了一种可用作 I 型 11β 羟类固醇脱氢酶抑制剂的化合物。 一种由式表示的化合物： 其药学上可接受的盐或溶液、 其中 R1 是任选取代的烷基或类似物、 R2 和 R4 中的一个是式中的基团：-Y-R5、 其中 Y 是 -O- 或类似物、 R5 是取代的烷基（取代基是任选取代的环烷基或类似物）、任选取代的支链烷基或类似物、 R2 和 R4 中的另一个是氢或任选取代的烷基、 R3 是式中的基团：-C(=O)-Z-R6、 其中 Z 是-NR7-或-NR7-W-、 R6 是任选取代的环烷基或类似物、 R7 是氢或任选取代的烷基、 W 是任选取代的亚烷基、 X 是 =N- 或类似物、 但 R2 为 2-(吗啉基)乙氧基、R3 为 N-(1-金刚烷基)氨基甲酰基、R1 为苄基的化合物除外。